Skip to main content

FDA Approvals

Jemperli (Dostarlimab) First Immunotherapy Approved for Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer

Loretta Fala

Ukoniq (Umbralisib) FDA Approved for Adults with Relapsed or Refractory Marginal-Zone Lymphoma or Follicular Lymphoman

Loretta Fala

Tabrecta (Capmatinib) First FDA-Approved Drug for Metastatic NSCLC with MET Exon 14 Skipping Mutation

Loretta Fala

Abecma (Idecabtagene Vicleucel) First-in-Class BCMA-Directed CAR T-Cell Therapy Approved for Relapsed or Refractory Multiple Myeloma

Loretta Fala

Truseltiq (Infigratinib) New Targeted Therapy FDA Approved for Advanced or Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

Loretta Fala

FDA Approvals, Leukemia, Lymphoma, Conference Highlights ASCO, Oncology

Rylaze FDA Approved as Part of a Treatment Regimen for Pediatric Leukemia and Lymphoma

Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO, Oncology

Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

FDA Approvals, Multiple Myeloma, Conference Highlights ASCO, Oncology

FDA Approves Darzalex Faspro plus Pomalyst and Dexamethasone for Multiple Myeloma

FDA Approvals, Conference Highlights ASCO

FDA Approves Avapritinib for Advanced Systemic Mastocytosis

FDA Approvals, Conference Highlights ASCO

Pembrolizumab plus Lenvatinib Combination Receives Regular Approval for Advanced Endometrial Carcinoma

Page 11 of 53
Results 101 - 110 of 524